Spyre Therapeutics
Announced 07 Dec 2023$180.0M Β· pipe Β· Biotechnology Research Β· United States
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering
βSpyre Therapeutics raises $180 million to advance anti-inflammatory drugs Oops, something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sports More News Today's news US Politics World Weather Climate change Science Originals Newsletters Games Life Health Parenting Horoscopes Shopping Food Travelβ
4 more sources tracked. Read the full press release and reporter coverage.
Sign up to read βInvestors: Access Biotechnology, Venrock Healthcare Capital Partners, RTW Investments, Braidwell, Fairmount, Cormorant Asset Management, Polar Capital, Boxer Capital, Deep Track Capital, Affinity Asset Advisors, Commodore Capital, Woodline Partners, Perceptive Advisors, Great Point Partners.